Skip to main content
SpringerLink
Log in

Pharmacokinetics of thio-TEPA at two different doses

  • Short Communication
  • Thio-TEPA, Pharmacokinetics, Ovarian Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Thio-TEPA pharmacokinetics were studied at doses of 20 mg and 30 mg in six patients treated for ovarian cancer. Considerable interindividual variation was encountered in its pharmacokinetics, which were dose-independent within the dose range studied and similar to those reported at far higher doses. Interindividual dosing of thio-TEPA based on an initial AUC estimation is suggested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Brown R, Herzig R, Fay J, Wolff S, Strandjord S, Egorin M, Herzig G, Washington U (1986) A phase I–II study of high-dose N N′ N″-triethylenethiophosphoramide (thiotepa) and autologous marrow transplantation (AMT) for refractory malignancies. Proc Am Soc Clin Oncol 5: 127

    Google Scholar 

  2. Cohen BE, Egorin MJ, Kolhepp EA, Aisner J, Gutierrez PL (1986) Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites. Cancer Treat Rep 70: 859

    Google Scholar 

  3. Eder J, Antman K, Elias A, Shea T, Siegel R, Schryber S, Mick R, Schnipper LE, Frei E III (1987) High-dose combination chemotherapy with continous infusion (CI) cyclophosphamide (CPA) and thiotepa (TSPA) with autologous bone marrow reinfusion (AMBT). Proc Am Soc Clin Oncol 6: 154

    Google Scholar 

  4. Hagen B, Walseth F, Walstad RA, Iversen T (1985) Gas chromatographic assay of triethylenethiophosphoramide in serum and urine. J Chromatogr Biomed Appl 345: 173

    Google Scholar 

  5. Hagen B, Walseth F, Walstad RA, Iversen T, Nilsen OG (1987) Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma. Cancer Chemother Pharmacol 19: 143

    Google Scholar 

  6. Hart RD, Perloff M, Holland JF (1981) One-day VATH therapy for advanced breast cancer refractory to prior chemotherapy. Cancer 48: 1522

    Google Scholar 

  7. Henderson IC, Greenspan E, Perloff M, Wolmark N (1986) Thiotepa in breast cancer. New perspectives. Proceedings of a roundtable discussion, Lederle Laboratories, Oct. 17, 1986, New Jersey, USA

  8. Henner WD, Shea TC, Furlong EA, Flaherty MD, Elias A, Eder JP, Antman K (1987) Pharmacokinetics of high-dose continous infusion thiotepa. Proc Am Soc Clin Oncol 6: 47

    Google Scholar 

  9. Powis G (1985) Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol 14: 177

    Google Scholar 

  10. Trump DL, Grossman SA, Thompson G, Murray K, Wharam M (1982) Treatment of neoplastic meningitis with intraventricular thio-TEPA and metotrexate. Cancer Treat Rep 66: 1549

    Google Scholar 

  11. Williams SF, Bitran JD, Kaminer L, Westbrook C, Jacobs R, Ashenhurst J, Robin E, Purl S, Beschorner J, Schroeder C, Golomb HM (1987) A phase I–II study of bialkylator chemotherapy, high-dose thiotepa and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer. J Clin Oncol 5: 260

    Google Scholar 

  12. Wilson AP, Neal FE (1981) In vitro sensitivity of human ovarian tumours to chemotherapeutic agents. Br J Cancer 44: 189

    Google Scholar 

  13. Zinke H, Benson RC Jr., Hilton JF, Taylor WF (1985) Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. J Urol 134: 1110

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Toxicology, University of Trondheim, N-7030, Trondheim, Norway

    Bjørn Hagen, Rolf A. Walstad & Odd G. Nilsen

  2. Department of Gynecology and Obstetrics, University of Trondheim, N-7030, Trondheim, Norway

    Bjørn Hagen, Rolf A. Walstad & Odd G. Nilsen

Authors
  1. Bjørn Hagen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rolf A. Walstad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Odd G. Nilsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The work described in this paper was supported by grants from The Regional Hospital (Trondheim), Trondheim Cancer Society (Trondheim) and The Norwegian Cancer Society (Oslo)

During the work Bjørn Hagen was a research fellow in The Norwegian Cancer Society

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hagen, B., Walstad, R.A. & Nilsen, O.G. Pharmacokinetics of thio-TEPA at two different doses. Cancer Chemother. Pharmacol. 22, 356–358 (1988). https://doi.org/10.1007/BF00254246

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00254246

Keywords

Search

Navigation